Cipher Pharmaceuticals
As of the edition of 20 October 2026, Cipher Pharmaceuticals runs 9 drugs, 9 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Fluorouracil | none listed | 2 |
| Tramadol | none listed | 3 |
| Isotretinoin | none listed | 3 |
| Fenofibrate | none listed | 3 |
| Tirofiban | none listed | 3 |
| Eflornithine | none listed | 3 |
| Vernakalant | none listed | 5 |
| Spinosad | none listed | 0 |
| Salicylic acid | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Cipher Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.